Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.
Animals
Antibodies, Viral
/ immunology
Antibody Formation
/ immunology
Cell Line
Dogs
Female
HEK293 Cells
Hemagglutination Inhibition Tests
/ methods
Humans
Influenza A Virus, H1N1 Subtype
/ immunology
Influenza A Virus, H3N2 Subtype
/ immunology
Influenza B virus
/ immunology
Influenza Vaccines
/ immunology
Influenza, Human
/ immunology
Madin Darby Canine Kidney Cells
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Orthomyxoviridae Infections
/ immunology
BM2-deficient
Cross-lineage protection
Drifted
Hemagglutination inhibition
Influenza B
Influenza vaccine
Intranasal
Live influenza
Single replication
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
26 07 2019
26 07 2019
Historique:
received:
27
01
2019
revised:
15
06
2019
accepted:
17
06
2019
pubmed:
10
7
2019
medline:
17
9
2020
entrez:
9
7
2019
Statut:
ppublish
Résumé
Both influenza A and B viruses cause outbreaks of seasonal influenza resulting in significant morbidity and mortality. There are two antigenically distinct lineages of influenza B virus, Yamagata lineage (YL) and Victoria lineage (VL). Since both B lineages have been co-circulating for years, more than 70% of influenza vaccines currently manufactured are quadrivalent consisting of influenza A (H1N1), influenza A (H3N2), influenza B (YL) and influenza B (VL) antigens. Although quadrivalent influenza vaccines tend to elevate immunity to both influenza B lineages, estimated overall vaccine efficacy against influenza B is still only around 42%. Thus, a more effective influenza B vaccine is needed. To meet this need, we generated BM2-deficient, single-replication (BM2SR) influenza B vaccine viruses that encode surface antigens from influenza B/Wisconsin/01/2010 (B/WI01, YL) and B/Brisbane/60/2008 (B/Bris60, VL) viruses. The BM2SR-WI01 and BM2SR-Bris60 vaccine viruses are replication-deficient in vitro and in vivo, and can only replicate in a cell line that expresses the complementing BM2 protein. Both BM2SR viruses were non-pathogenic to mice, and vaccinated animals showed elevated mucosal and serum antibody responses to both Yamagata and Victoria lineages in addition to cellular responses. Serum antibody responses included lineage-specific hemagglutinin inhibition antibody (HAI) responses as well as responses to the stem region of the hemagglutinin (HA). BM2SR vaccine viruses provided apparent sterilizing immunity to mice against intra- and inter-lineage drifted B virus challenge. The data presented here support the feasibility of BM2SR as a platform for next-generation trivalent influenza vaccine development.
Identifiants
pubmed: 31280945
pii: S0264-410X(19)30805-9
doi: 10.1016/j.vaccine.2019.06.043
pmc: PMC6658110
mid: NIHMS1533695
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4533-4542Subventions
Organisme : NIAID NIH HHS
ID : R41 AI109925
Pays : United States
Organisme : NIAID NIH HHS
ID : R44 AI109925
Pays : United States
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9345-50
pubmed: 10430945
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11411-6
pubmed: 12172012
J Virol. 2004 Jun;78(11):5576-83
pubmed: 15140954
Am J Respir Crit Care Med. 2006 Nov 1;174(9):1011-7
pubmed: 16917113
J Virol. 2009 Jun;83(11):5947-50
pubmed: 19321619
Vaccine. 2010 Feb 25;28(9):2149-56
pubmed: 20003926
Vaccine. 2010 Sep 7;28 Suppl 4:D45-53
pubmed: 20713260
Vaccine. 2011 Mar 9;29(12):2308-12
pubmed: 21272601
Vaccine. 2011 Jul 12;29(31):4947-52
pubmed: 21596087
Pediatr Infect Dis J. 2011 Oct;30(10):833-9
pubmed: 21857263
Drugs. 2011 Aug 20;71(12):1591-622
pubmed: 21861544
Hum Vaccin Immunother. 2012 Jan;8(1):76-80
pubmed: 22251995
Hum Vaccin Immunother. 2012 Jan;8(1):81-8
pubmed: 22252006
PLoS One. 2012;7(6):e38929
pubmed: 22745690
Science. 2012 Sep 14;337(6100):1343-8
pubmed: 22878502
Virology. 1990 Mar;175(1):59-68
pubmed: 2309452
Expert Rev Vaccines. 2012 Nov;11(11):1293-303
pubmed: 23151111
Am J Public Health. 2013 Mar;103(3):e43-51
pubmed: 23327249
Euro Surveill. 2013 Jan 31;18(5):null
pubmed: 23399424
Euro Surveill. 2013 Jan 31;18(5):null
pubmed: 23399425
BMC Infect Dis. 2013 May 20;13:224
pubmed: 23688546
BMC Med. 2013 Jun 25;11:153
pubmed: 23800265
Curr Opin Virol. 2013 Oct;3(5):521-30
pubmed: 23978327
Clin Infect Dis. 2014 Dec 1;59(11):1519-24
pubmed: 25139969
J Gen Virol. 2015 Aug;96(8):2061-73
pubmed: 25900135
Influenza Other Respir Viruses. 2015 Aug;9 Suppl 1:3-12
pubmed: 26256290
J Prev Med Hyg. 2016;57(1):E28-33
pubmed: 27346937
Vaccine. 2016 Jul 29;34(35):4092-4102
pubmed: 27381642
Vaccine. 2016 Sep 30;34(42):5090-5098
pubmed: 27595896
Clin Infect Dis. 2016 Dec 29;64(5):544-550
pubmed: 28039340
J Virol. 2017 May 26;91(12):
pubmed: 28356526
Vaccine. 2017 Jul 24;35(33):4177-4183
pubmed: 28668565
J Infect Dis. 2018 Feb 14;217(5):731-741
pubmed: 29220496
J Infect Dis. 2017 Dec 27;217(1):3-11
pubmed: 29294018
J Infect Dis. 2018 Jan 30;217(4):548-559
pubmed: 29325138
Euro Surveill. 2018 Feb;23(5):
pubmed: 29409570
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29507069
Vaccine. 2018 Sep 25;36(40):6030-6038
pubmed: 29709447
Biochem Biophys Res Commun. 2018 Jul 12;502(2):226-231
pubmed: 29792863
Biomed Res Int. 2018 Aug 30;2018:9695628
pubmed: 30246028
J Virol. 2019 Mar 5;93(6):
pubmed: 30626682
Nat Commun. 2019 Jan 18;10(1):324
pubmed: 30659197
Am J Epidemiol. 1969 Apr;89(4):422-34
pubmed: 4305198